Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer

M Arbyn, G Ronco, A Anttila, CJLM Meijer, M Poljak… - Vaccine, 2012 - Elsevier
More than ever, clinicians need regularly updated reviews given the continuously increasing
amount of new information regarding innovative cervical cancer prevention methods. A …

Human papillomavirus testing in the prevention of cervical cancer

M Schiffman, N Wentzensen… - Journal of the …, 2011 - academic.oup.com
Strong evidence now supports the adoption of cervical cancer prevention strategies that
explicitly focus on persistent infection with the causal agent, human papillomavirus (HPV) …

[HTML][HTML] Worldwide burden of cervical cancer in 2008

M Arbyn, X Castellsagué, S de Sanjosé, L Bruni… - Annals of oncology, 2011 - Elsevier
Background The knowledge that persistent human papillomavirus infection is the main
cause of cervical cancer has resulted in the development of assays that detect nucleic acids …

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

G Ronco, P Giorgi-Rossi, F Carozzi, M Confortini… - The lancet …, 2010 - thelancet.com
Background Human papillomavirus (HPV) testing is known to be more sensitive, but less
specific than cytology for detecting cervical intraepithelial neoplasia (CIN). We assessed the …

Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective

S Finocchario-Kessler, C Wexler, M Maloba… - BMC women's …, 2016 - Springer
Abstract Background Women living in Africa experience the highest burden of cervical
cancer. Research and investment to improve vaccination, screening, and treatment efforts …

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice

HA Katki, WK Kinney, B Fetterman, T Lorey… - The lancet …, 2011 - thelancet.com
Background Concurrent testing for human papillomavirus (HPV) and cervical cytology (co-
testing) is an approved alternative to cytology alone in women aged 30 years and older. We …

[HTML][HTML] Asociación entre conocimientos acerca del cáncer de cuello uterino y realizarse una prueba de Papanicolaou en mujeres peruanas

G Bendezu-Quispe… - Revista peruana de …, 2020 - SciELO Public Health
Objetivos: Estimar la asociación entre tener conocimientos acerca del cáncer de cuello
uterino (CaCu) y re alizarse una prueba de Papanicolaou (PAP) en mujeres peruanas …

A review of methods for detect human Papillomavirusinfection

ALP Abreu, RP Souza, F Gimenes, MEL Consolaro - Virology journal, 2012 - Springer
Human Papillomavirus (HPV) is the most common sexually transmitted virus. Worldwide, the
most common high-risk (HR)-HPV are-16/18, and approximately 70% of cervical cancers …

Is infrared spectroscopy ready for the clinic?

D Finlayson, C Rinaldi, MJ Baker - Analytical chemistry, 2019 - ACS Publications
Fourier transform-infrared spectroscopy (FT-IR) represents an attractive molecular
diagnostic modality for translation to the clinic, where comprehensive chemical profiling of …

A high fidelity CRISPR/Cas12a based lateral flow biosensor for the detection of HPV16 and HPV18

O Mukama, T Yuan, Z He, Z Li… - Sensors and Actuators B …, 2020 - Elsevier
Abnormal growth of uterine cervix cells may eventually lead to cervical cancer, which is
mainly associated with the two most prevalent types of Human Papilloma Virus (HPV) …